Autoantibodies against T-cell receptors have been found in two alloimmunization situations in humans: renal transplantation and pregnancy. We carried out longitudinal studies of human heart transplant recipients monitoring their autoantibody production to a recombinant single chain T-cell receptor V alpha/V beta construct, a set of nested, overlapping peptides duplicating the complete covalent structure of an individual T-cell receptor beta chain and a set of peptides duplicating the first complementarity determining segments of 24 distinct human V beta gene products in order to define the time course, epitope specificity and recognition heterogeneity of the response. Autoantibodies against intact and peptide-defined V beta and C beta determinants were generated following human heart allotransplantation. The responses generally show an increase following transplantation that subsequently decreases with time, a result which is consistent with a single immunization. However, some patients showed elevated responses as long as 12 months following the transplant. Autoantibody anti-CDR1 spectrotype analyses detected individual differences among patients, but 5 of 8 patients characterized in detail showed elevated IgG binding to CDR1 peptide epitopes of V beta 6.1, 21.1 and 22.1 gene products. Autoantibodies to CDR1 epitopes of V beta 7.1 and 8.1 were high pretransplant and remained high, although the relative increases with respect to the pretransplant values were not as impressive as those for the above CDR1 epitopes and others usually present in low quantity, e.g. anti-V beta 2.1, 3.1 and 24.1. Although there was great disparity between the MHC haplotypes of donors and recipients, and individual differences among patients, the degree of restriction in the autoantibody response was surprising and suggests a common step in recognition and regulation of the response to allografts.
Download full-text PDF |
Source |
---|
Cancer Biol Ther
December 2025
Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Adaptive immune resistance in cancer describes the various mechanisms by which tumors adapt to evade anti-tumor immune responses. IFN-γ induction of programmed death-ligand 1 (PD-L1) was the first defined and validated adaptive immune resistance mechanism. The endoplasmic reticulum (ER) is central to adaptive immune resistance as immune modulatory secreted and integral membrane proteins are dependent on ER.
View Article and Find Full Text PDFMol Ther
January 2025
Brown Center for Immunotherapy. Indiana University School of Medicine. 975 W. Walnut St., IB554A, Indianapolis, IN 46202. Electronic address:
Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment and is now being explored for other diseases, such as autoimmune disorders. While the tumor microenvironment (TME) in cancer is often immunosuppressive, in autoimmune diseases, the environment is typically inflammatory. Both environments can negatively impact CAR T cell survival: the former through direct suppression, hypoxia, and nutrient deprivation, and the latter through chronic T cell receptor (TCR) engagement, risking exhaustion.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Evidence has shown that T-cell receptors (TCRs) that recognize the same epitopes may not be the exact TCR clonotypes but have slightly different TCR sequences. However, the changes in the genomic and transcriptomic signatures of these highly homologous T cells during immunotherapy remain unknown. Here, we examined the evolutionary features in circulating TCR clonotypes observed in tumors (tumor-infiltrating lymphocyte (TIL)-TCRs) by combining single-cell RNA/TCR sequencing of longitudinal blood samples and TCR sequencing of tumor tissue from a patient treated with anti-cytotoxic T-lymphocyte-associated protein 4/programmed cell death protein-1 therapy.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand
Background: B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 across various solid tumors and developed novel monoclonal antibodies (mAbs) targeting B7-H3 for CAR T cell therapy.
Methods: Expression of B7-H3 across various solid tumors was evaluated using RNA-seq data from TCGA, TARGET, and GTEx datasets and by flow cytometry staining.
Sci China Life Sci
January 2025
The Second Affiliated Hospital, The First Affiliated Hospital, School of Public Health, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Zinc homeostasis plays an essential role in maintaining immune function and is tightly regulated by zinc transporters. We previously reported that the zinc transporter SLC39A10, located in the cell membrane, critically regulates the susceptibility of macrophages to inflammatory stimuli; however, the functional role of SLC39A10 in T cells is currently unknown. Here, we identified two SNPs in SLC39A10 that are associated with inflammatory bowel disease (IBD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!